aldosterone has been researched along with Myocardial Infarction in 192 studies
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of patients with acute myocardial infarction eligible for the International Study of Infarct Survival-4, randomized to captopril (n = 30) or placebo (n = 33), the captopril group had a significant decrease in blood adrenaline on day 3 compared with baseline values." | 9.08 | Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4. ( Budaj, A; Ceremuzyński, L; Herbaczyńska-Cedro, K; Kokot, F, 1998) |
| "A 12 week randomised, double blind, placebo controlled study on the effect of enalapril (5-20 mg daily) on the concentration of plasma atrial natriuretic peptide level and activity of the sympathetic nervous system and renin angiotensin system was done on 27 patients who had suffered an uncomplicated acute myocardial infarction two to six months earlier." | 9.07 | Effect of enalapril on plasma atrial natriuretic peptide in late recovery phase of acute myocardial infarction. ( Hirvonen, T; Mustonen, J; Pyörälä, K; Remes, J; Tenhunen, M; Tikkanen, I, 1991) |
| "Plasma neurohormones were sequentially analysed in 98 patients with acute myocardial infarction randomized to treatment with enalapril or placebo for 4-6 months." | 9.07 | Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling. ( Held, P; Sigurdsson, A; Swedberg, K; Wall, B, 1993) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 8.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| "Both aldosterone and arginine vasopressin (AVP) are produced in the heart and may participate in cardiac fibrosis." | 8.12 | Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction. ( Gao, X; Li, J; Lu, G; Peng, L; Zhai, YS, 2022) |
| "To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome." | 7.85 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017) |
| " We investigated the effects of adding the direct renin inhibitor (DRI), aliskiren, to an ACEI or an ARB on monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction (AMI)." | 7.78 | Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction. ( Akasaka, T; Imanishi, T; Ino, Y; Ishibashi, K; Kashiwagi, M; Kitabata, H; Komukai, K; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Sougawa, H; Tanimoto, T; Tsujioka, H, 2012) |
| "Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR." | 7.74 | [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 7.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 7.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| "The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure." | 7.72 | Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. ( Busch, AE; Gerl, M; Licher, T; Ruetten, H; Rungwerth, K; Schäfer, S; Schindler, U, 2004) |
| "Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)." | 7.72 | Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004) |
| "Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI)." | 7.72 | Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. ( Lal, A; Leenen, FH; Veinot, JP, 2004) |
| "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure." | 7.71 | Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. ( Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M, 2002) |
| " This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration." | 7.70 | Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999) |
| "The effect of enalapril during healing between 1 day and 6 weeks after myocardial infarction on in vivo changes in ventricular size, shape, mass, and function (asynergy, or akinesis and dyskinesis, and ejection fraction), as determined by serial two-dimensional echocardiography, hemodynamics, postmortem topography (planimetered short- and long-axis ventricular contours), and collagen content (determined by levels of hydroxyproline, a marker for collagen), was measured in 25 instrumented dogs." | 7.69 | Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. ( Blinston, GE; Jugdutt, BI; Jugdutt, SJ; Khan, MI, 1995) |
| "Plasma atrial natriuretic factor (ANF), renin activity (PRA), aldosterone and antidiuretic hormone (ADH) were determined in 16 patients with uncomplicated acute myocardial infarction (AMI) for 7 days in all patients and in six patients for 8 more days." | 7.68 | Plasma atrial natriuretic factor in patients with acute myocardial infarction. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1990) |
| "Plasma atrial natriuretic factor, aldosterone, renin activity, and antidiuretic hormone were studied in low output heart failure syndromes: cardiogenic shock in ten patients with acute myocardial infarction of the anterior wall (first group), hypovolemic shock after melena from peptic ulcer in ten subjects (second group), and hypotension with bradycardia syndrome in ten patients with acute myocardial infarction of the inferior wall (third group)." | 7.68 | Plasma atrial natriuretic factor in low output heart failure syndromes. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1990) |
| "A serial measurements of plasma renin activity (PRA), serum angiotensin converting enzyme activity (ACE), concentrations of plasma angiotensin II (AII) and plasma aldosterone (Ald) in 38 consecutive patients with acute myocardial infarction (AMI) or suspected AMI showed that PRA, AII and Ald levels increased in patients with AMI, especially within first week after onset, and were significantly higher in those cases with severe complications." | 7.68 | [The changes in renin-angiotensin-aldosterone system in acute myocardial infarction and the effects of converting enzyme inhibitor-captopril]. ( Jiang, M, 1991) |
| "Plasma atrial natriuretic factor (ANF) levels were measured in 29 patients who had normal atrial hemodynamics on days 4 and 8 after an uncomplicated acute myocardial infarction (AMI)." | 7.68 | Plasma atrial natriuretic factor in uncomplicated acute myocardial infarction. ( Antonopoulos, A; Aspiotis, N; Kyriakidis, M; Marakas, S; Petropoulakis, P; Toutouzas, P; Tselika, C, 1993) |
| "The aim of this paper was to study plasma atrial natriuretic factor, renin activity, aldosterone and antidiuretic hormone in low-output heart failure syndromes such as cardiogenic shock, hypovolemic shock and hypotension with bradycardia syndrome." | 7.67 | [Atrial natriuretic factor in cardiogenic shock, in hypovolemic shock and in the bradycardia-hypotension syndrome following acute myocardial infarction]. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1989) |
| "The angiotensin-converting enzyme inhibitor, captopril, was given to 19 patients with severe heart failure." | 7.66 | Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. ( Boomsma, F; Hugenholtz, PG; Laird-Meeter, K; Man in't veld, AJ; Schalekamp, MA; Simoons, ML; Wenting, GJ; Woittiez, AJ, 1983) |
| "Right ventricular dysfunction was defined as CMR RV ejection fraction < 50%." | 6.80 | Usefulness of Speckle-Tracking Imaging for Right Ventricular Assessment after Acute Myocardial Infarction: A Magnetic Resonance Imaging/Echocardiographic Comparison within the Relation between Aldosterone and Cardiac Remodeling after Myocardial Infarction ( Beaumont, M; Girerd, N; Huttin, O; Juillière, Y; Lemarié, J; Lemoine, S; Mandry, D; Marie, PY; Moulin, F; Selton-Suty, C, 2015) |
| "Non-culprit intermediate coronary atherosclerosis was assessed on intravascular ultrasound." | 6.77 | Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. ( Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2." | 6.69 | Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999) |
| " All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12." | 6.68 | The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995) |
| "Aldosterone is an important mediator of the renin-angiotensin-aldosterone system (RAAS) that plays a major role in the pathophysiology of cardiovascular disease as well as regulation of extracellular fluid volume and potassium." | 6.43 | Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. ( Cohn, JN; Colucci, W, 2006) |
| "Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction." | 6.42 | Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004) |
| "Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature." | 5.40 | Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014) |
| "Cardiac rupture is a catastrophic complication that occurs after acute myocardial infarction (MI) and, at present, there are no effective pharmacological strategies for preventing this condition." | 5.40 | Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53. ( Bin, J; Cao, S; Chen, B; Fu, Y; Huang, Q; Huang, X; Kitakaze, M; Liao, Y; Lu, D; Xu, D; Zhang, J, 2014) |
| "Aldosterone levels were assayed in plasma taken from 583 patients within 24-96 h following acute myocardial infarction (MI)." | 5.35 | Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. ( Frampton, CM; Nicholls, MG; Palmer, BR; Pilbrow, AP; Richards, AM; Skelton, L; Yandle, TG, 2008) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 5.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "High aldosterone levels were associated with an almost stepwise increase in rates of in-hospital death (P=0." | 5.33 | High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. ( Barthélémy, O; Benoliel, JJ; Beygui, F; Collet, JP; Dumaine, R; Montalescot, G; Vignolles, N, 2006) |
| "Aldosterone values were highly correlated with the urine potassium/sodium ratio." | 5.27 | The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction. ( Ceremuzyński, L; Michorowski, B, 1983) |
| "This was a double-blind, randomized comparison of isosorbide-5-mononitrate (IS-5-MN), 60 mg given orally, once daily for 11 months to patients (n = 47) with left ventricular (LV) dysfunction following acute myocardial infarction (AMI)." | 5.12 | Neurohumoral changes in patients with left ventricular dysfunction following acute myocardial infarction and the effect of nitrate therapy: a randomized, double-blind, placebo-controlled long-term study. ( Ohlin, H; Roijer, A; Thilen, U; Tingberg, E, 2006) |
| "In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%." | 5.11 | RALES, EPHESUS and redox. ( Funder, JW, 2005) |
| "Of patients with acute myocardial infarction eligible for the International Study of Infarct Survival-4, randomized to captopril (n = 30) or placebo (n = 33), the captopril group had a significant decrease in blood adrenaline on day 3 compared with baseline values." | 5.08 | Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4. ( Budaj, A; Ceremuzyński, L; Herbaczyńska-Cedro, K; Kokot, F, 1998) |
| "Plasma neurohormones were sequentially analysed in 98 patients with acute myocardial infarction randomized to treatment with enalapril or placebo for 4-6 months." | 5.07 | Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling. ( Held, P; Sigurdsson, A; Swedberg, K; Wall, B, 1993) |
| "A 12 week randomised, double blind, placebo controlled study on the effect of enalapril (5-20 mg daily) on the concentration of plasma atrial natriuretic peptide level and activity of the sympathetic nervous system and renin angiotensin system was done on 27 patients who had suffered an uncomplicated acute myocardial infarction two to six months earlier." | 5.07 | Effect of enalapril on plasma atrial natriuretic peptide in late recovery phase of acute myocardial infarction. ( Hirvonen, T; Mustonen, J; Pyörälä, K; Remes, J; Tenhunen, M; Tikkanen, I, 1991) |
| " The selective aldosterone blocker, eplerenone (Inspra), is under development for human therapeutic use for treatment of hypertension and heart failure post-myocardial infarction (MI)." | 4.82 | Aldosterone target organ protection by eplerenone. ( McMahon, EG; Rocha, R; Rudolph, AE, 2004) |
| " More recently, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study has provided firm support for the use of eplerenone (Inspra, Pfizer) in heart failure following acute myocardial infarction in addition to neurohormonal blockade with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta-blockers." | 4.82 | Eplerenone in the treatment of chronic heart failure. ( Krum, H; Liew, D, 2004) |
| "Both aldosterone and arginine vasopressin (AVP) are produced in the heart and may participate in cardiac fibrosis." | 4.12 | Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction. ( Gao, X; Li, J; Lu, G; Peng, L; Zhai, YS, 2022) |
| "To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome." | 3.85 | Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. ( Ballantyne, CM; Barter, PJ; Gunzburger, E; Kallend, D; Kittelson, J; Leiter, LA; Leitersdorf, E; McMurray, JJ; Nicholls, SJ; Olsson, AG; Pitts, R; Schwartz, GG; Shah, PK; Tardif, JC, 2017) |
| " We investigated the effects of adding the direct renin inhibitor (DRI), aliskiren, to an ACEI or an ARB on monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction (AMI)." | 3.78 | Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction. ( Akasaka, T; Imanishi, T; Ino, Y; Ishibashi, K; Kashiwagi, M; Kitabata, H; Komukai, K; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Sougawa, H; Tanimoto, T; Tsujioka, H, 2012) |
| "Losartan may reduce reactive fibrosis not only by attenuating the Ald signaling pathway but also by decreasing the expression of MR." | 3.74 | [Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats]. ( Bai, SC; Deng, LH; Huang, P; Su, L; Wen, YW; Wu, ZL; Xu, DL, 2008) |
| "Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies." | 3.73 | Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006) |
| " The aim of the present study was to evaluate the role of aldosterone and angiotensin II on formation of left ventricular fibrosis induced by chronic beta-adrenergic stimulation with isoproterenol (iso) in the rat heart failure model induced by myocardial infarction (MI)." | 3.73 | Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist. ( Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM, 2005) |
| "Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI)." | 3.72 | Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. ( Lal, A; Leenen, FH; Veinot, JP, 2004) |
| "Adrenomedullin (AM) is expressed in cardiac tissue, and plasma AM levels increase in patients with acute myocardial infarction (MI)." | 3.72 | Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. ( Asada, Y; Cao, Y; Eto, T; Imamura, T; Kangawa, K; Kato, J; Kitamura, K; Marutsuka, K; Nakamura, R; Onitsuka, H, 2004) |
| "The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure." | 3.72 | Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. ( Busch, AE; Gerl, M; Licher, T; Ruetten, H; Rungwerth, K; Schäfer, S; Schindler, U, 2004) |
| "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure." | 3.71 | Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. ( Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M, 2002) |
| " This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration." | 3.70 | Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999) |
| "The effect of enalapril during healing between 1 day and 6 weeks after myocardial infarction on in vivo changes in ventricular size, shape, mass, and function (asynergy, or akinesis and dyskinesis, and ejection fraction), as determined by serial two-dimensional echocardiography, hemodynamics, postmortem topography (planimetered short- and long-axis ventricular contours), and collagen content (determined by levels of hydroxyproline, a marker for collagen), was measured in 25 instrumented dogs." | 3.69 | Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog. ( Blinston, GE; Jugdutt, BI; Jugdutt, SJ; Khan, MI, 1995) |
| "Plasma atrial natriuretic factor (ANF), renin activity (PRA), aldosterone and antidiuretic hormone (ADH) were determined in 16 patients with uncomplicated acute myocardial infarction (AMI) for 7 days in all patients and in six patients for 8 more days." | 3.68 | Plasma atrial natriuretic factor in patients with acute myocardial infarction. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1990) |
| "Plasma atrial natriuretic factor, aldosterone, renin activity, and antidiuretic hormone were studied in low output heart failure syndromes: cardiogenic shock in ten patients with acute myocardial infarction of the anterior wall (first group), hypovolemic shock after melena from peptic ulcer in ten subjects (second group), and hypotension with bradycardia syndrome in ten patients with acute myocardial infarction of the inferior wall (third group)." | 3.68 | Plasma atrial natriuretic factor in low output heart failure syndromes. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1990) |
| "Plasma levels of atrial natriuretic peptide (ANP), angiotensin II, aldosterone, and catecholamines were followed for 1 month and then for 4 to 6 months in 55 patients with acute myocardial infarction." | 3.68 | Short- and long-term neurohormonal activation following acute myocardial infarction. ( Held, P; Sigurdsson, A; Swedberg, K, 1993) |
| "Plasma atrial natriuretic factor (ANF) levels were measured in 29 patients who had normal atrial hemodynamics on days 4 and 8 after an uncomplicated acute myocardial infarction (AMI)." | 3.68 | Plasma atrial natriuretic factor in uncomplicated acute myocardial infarction. ( Antonopoulos, A; Aspiotis, N; Kyriakidis, M; Marakas, S; Petropoulakis, P; Toutouzas, P; Tselika, C, 1993) |
| "A serial measurements of plasma renin activity (PRA), serum angiotensin converting enzyme activity (ACE), concentrations of plasma angiotensin II (AII) and plasma aldosterone (Ald) in 38 consecutive patients with acute myocardial infarction (AMI) or suspected AMI showed that PRA, AII and Ald levels increased in patients with AMI, especially within first week after onset, and were significantly higher in those cases with severe complications." | 3.68 | [The changes in renin-angiotensin-aldosterone system in acute myocardial infarction and the effects of converting enzyme inhibitor-captopril]. ( Jiang, M, 1991) |
| "Acute myocardial infarction is associated with complex neuroendocrine changes, including release of arginine vasopressin, norepinephrine, and epinephrine, and activation of the renin-angiotensin system." | 3.67 | Neuroendocrine changes in acute myocardial infarction. ( Cobbe, SM; McAlpine, HM, 1988) |
| "The aim of this paper was to study plasma atrial natriuretic factor, renin activity, aldosterone and antidiuretic hormone in low-output heart failure syndromes such as cardiogenic shock, hypovolemic shock and hypotension with bradycardia syndrome." | 3.67 | [Atrial natriuretic factor in cardiogenic shock, in hypovolemic shock and in the bradycardia-hypotension syndrome following acute myocardial infarction]. ( Bernardi, P; Capelli, M; Fontana, F; Spagnolo, N, 1989) |
| "In patients with mild hypertension, flurbiprofen in a dose of 100 mg daily for 7 days attenuated the hypotensive effect of a single dose of propranolol 80 mg but not of atenolol 100 mg." | 3.67 | Flurbiprofen interaction with single doses of atenolol and propranolol. ( Hawksworth, GM; McLean, I; Petrie, JC; Webster, J, 1984) |
| "The angiotensin-converting enzyme inhibitor, captopril, was given to 19 patients with severe heart failure." | 3.66 | Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone. ( Boomsma, F; Hugenholtz, PG; Laird-Meeter, K; Man in't veld, AJ; Schalekamp, MA; Simoons, ML; Wenting, GJ; Woittiez, AJ, 1983) |
| "Early detection of adverse effects of novel therapies and understanding of their mechanisms could improve the safety and efficiency of drug development." | 2.87 | Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. ( DeLisle, RK; Ganz, P; Hyde, C; Malarstig, A; Murthy, AC; Ostroff, R; Segal, MR; Weiss, SJ; Williams, SA, 2018) |
| "Right ventricular dysfunction was defined as CMR RV ejection fraction < 50%." | 2.80 | Usefulness of Speckle-Tracking Imaging for Right Ventricular Assessment after Acute Myocardial Infarction: A Magnetic Resonance Imaging/Echocardiographic Comparison within the Relation between Aldosterone and Cardiac Remodeling after Myocardial Infarction ( Beaumont, M; Girerd, N; Huttin, O; Juillière, Y; Lemarié, J; Lemoine, S; Mandry, D; Marie, PY; Moulin, F; Selton-Suty, C, 2015) |
| "Non-culprit intermediate coronary atherosclerosis was assessed on intravascular ultrasound." | 2.77 | Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. ( Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients." | 2.72 | RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. ( Cambrón-Mora, D; Garcia-Garduño, TC; Padilla-Gutierrez, JR; Valle, Y, 2021) |
| "Treatment with captopril affected only plasma renin activity (increase) and aldosterone (decrease)." | 2.69 | Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. ( Bichet, D; Ciampi, A; de Champlain, J; Harel, F; Moyé, LA; Pfeffer, M; Rouleau, JL; Vantrimpont, P, 1998) |
| "Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2." | 2.69 | Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999) |
| " All patients received three dosing regimens administered in random order: (a) intravenous frusemide: 40 mg bolus then 40 mg h-1 for 3 h, (b) captopril: two 12." | 2.68 | The renin angiotensin aldosterone system and frusemide response in congestive heart failure. ( Cerimele, B; Greene, P; Reed, S; Ryan, T; Schwertschlag, U; Voelker, J; Weinberger, M, 1995) |
| "Treatment with prazosin for one month also reduced systemic vascular resistance by 8%, renal vascular resistance increased by 20%, and renal blood flow and the percentage of the cardiac output going to the kidney fell by 14% and 26%." | 2.66 | The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, P; Sutton, G, 1986) |
| "Aldosterone is an important mediator of the renin-angiotensin-aldosterone system (RAAS) that plays a major role in the pathophysiology of cardiovascular disease as well as regulation of extracellular fluid volume and potassium." | 2.43 | Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. ( Cohn, JN; Colucci, W, 2006) |
| "Aldosterone blockade has been shown to be effective in reducing total mortality as well as hospitalization for heart failure in patients with systolic left ventricular dysfunction (SLVD) due to chronic heart failure and in patients with SLVD post acute myocardial infarction." | 2.42 | Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. ( Pitt, B, 2004) |
| "Primary aldosteronism is now recognized as the most common cause of secondary hypertension." | 1.72 | Primary aldosteronism presenting as embolic myocardial infarction. ( Jin, HY; Kim, YJ; Lee, HW; Lee, KA, 2022) |
| "A rat model of ventricular remodeling after myocardial infarction was established by left coronary artery ligation." | 1.42 | Cardioprotective effect of polydatin on ventricular remodeling after myocardial infarction in coronary artery ligation rats. ( Chen, C; Gao, J; Gao, Y; Guo, J; Wang, H; Wu, R, 2015) |
| "Cardiac rupture is a catastrophic complication that occurs after acute myocardial infarction (MI) and, at present, there are no effective pharmacological strategies for preventing this condition." | 1.40 | Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53. ( Bin, J; Cao, S; Chen, B; Fu, Y; Huang, Q; Huang, X; Kitakaze, M; Liao, Y; Lu, D; Xu, D; Zhang, J, 2014) |
| "Aldosterone appears to be a main marker of adverse clinical outcome, in accordance with the literature." | 1.40 | Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. ( Arnone, G; Arnone, MT; Assennato, P; Corrado, E; Mignano, A; Novo, G; Novo, S; Pitruzzella, V; Rotolo, A, 2014) |
| " Here we show that aldosterone exerts direct toxic actions on myocardium by oxidative activation of CaMKII, causing cardiac rupture and increased mortality in mice after myocardial infarction." | 1.37 | Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. ( Allamargot, C; Anderson, ME; Blankesteijn, WM; Grumbach, IM; Guan, X; He, BJ; Heymans, S; Joiner, ML; Koval, OM; Kutschke, W; Luczak, ED; Mohler, PJ; Sigmund, CD; Singh, MV; Spitz, DR; Swaminathan, PD; Weiss, RM; Yang, J; Zimmerman, K, 2011) |
| "Aldosterone levels were assayed in plasma taken from 583 patients within 24-96 h following acute myocardial infarction (MI)." | 1.35 | Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. ( Frampton, CM; Nicholls, MG; Palmer, BR; Pilbrow, AP; Richards, AM; Skelton, L; Yandle, TG, 2008) |
| "High aldosterone levels were associated with an almost stepwise increase in rates of in-hospital death (P=0." | 1.33 | High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. ( Barthélémy, O; Benoliel, JJ; Beygui, F; Collet, JP; Dumaine, R; Montalescot, G; Vignolles, N, 2006) |
| "Aldosterone was increased markedly in both the LV and RV at 8 weeks post-MI." | 1.33 | Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen. ( Ganten, D; Lal, A; Leenen, FH; Veinot, JP, 2005) |
| "The study was made in 45 patients with congestive heart failure treated in the Department of Cardiology." | 1.32 | [Cytokines and remodeling of the heart in patients with congestive heart failure]. ( Jołda-Mydłowska, B; Salomon, P, 2003) |
| "Collagen scar formation was evaluated by measurement of serum concentrations of the aminoterminal propeptide of type III procollagen (PIIINP), the aminoterminal propeptide of type I procollagen (intact PINP), and the carboxyterminal propeptide of type I procollagen (PICP)." | 1.30 | Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. ( Ikäheimo, M; Jounela, A; Lumme, J; Niemelä, M; Peuhkurinen, K; Risteli, J; Uusimaa, P, 1997) |
| "Aldosterone values were highly correlated with the urine potassium/sodium ratio." | 1.27 | The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction. ( Ceremuzyński, L; Michorowski, B, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 45 (23.44) | 18.7374 |
| 1990's | 42 (21.88) | 18.2507 |
| 2000's | 56 (29.17) | 29.6817 |
| 2010's | 35 (18.23) | 24.3611 |
| 2020's | 14 (7.29) | 2.80 |
| Authors | Studies |
|---|---|
| Parksook, WW | 1 |
| Williams, GH | 1 |
| Lee, HW | 1 |
| Kim, YJ | 1 |
| Jin, HY | 1 |
| Lee, KA | 1 |
| Salama, ABM | 1 |
| Abouleisa, RRE | 1 |
| Ou, Q | 1 |
| Tang, XL | 1 |
| Alhariry, N | 1 |
| Hassan, S | 1 |
| Gebreil, A | 1 |
| Dastagir, M | 1 |
| Abdulwali, F | 1 |
| Bolli, R | 1 |
| Mohamed, TMA | 1 |
| Zhai, YS | 2 |
| Li, J | 3 |
| Peng, L | 2 |
| Lu, G | 2 |
| Gao, X | 2 |
| Lee, SH | 1 |
| Rhee, TM | 1 |
| Shin, D | 1 |
| Hong, D | 1 |
| Choi, KH | 1 |
| Kim, HK | 1 |
| Park, TK | 1 |
| Yang, JH | 1 |
| Song, YB | 1 |
| Hahn, JY | 1 |
| Choi, SH | 1 |
| Chae, SC | 1 |
| Cho, MC | 1 |
| Kim, CJ | 1 |
| Kim, JH | 1 |
| Kim, HS | 1 |
| Gwon, HC | 1 |
| Jeong, MH | 1 |
| Lee, JM | 1 |
| Monzo, L | 1 |
| Huttin, O | 2 |
| Ferreira, JP | 1 |
| Lamiral, Z | 1 |
| Bozec, E | 1 |
| Beaumont, M | 2 |
| Micard, E | 1 |
| Baudry, G | 1 |
| Marie, PY | 2 |
| Eschalier, R | 1 |
| Rossignol, P | 1 |
| Zannad, F | 3 |
| Girerd, N | 2 |
| Klapper-Goldstein, H | 2 |
| Murninkas, M | 2 |
| Gillis, R | 2 |
| Mulla, W | 1 |
| Levanon, E | 1 |
| Elyagon, S | 2 |
| Schuster, R | 1 |
| Danan, D | 1 |
| Cohen, H | 1 |
| Etzion, Y | 2 |
| Azizi, M | 1 |
| Dragasevic, N | 1 |
| Jakovljevic, V | 1 |
| Zivkovic, V | 1 |
| Draginic, N | 1 |
| Andjic, M | 1 |
| Bolevich, S | 1 |
| Jovic, S | 1 |
| Verma, A | 1 |
| Pittala, S | 1 |
| Paul, A | 1 |
| Shoshan-Barmatz, V | 1 |
| Zhang, X | 1 |
| Shao, C | 1 |
| Cheng, S | 2 |
| Zhu, Y | 1 |
| Liang, B | 1 |
| Gu, N | 1 |
| Guitart-Mampel, M | 1 |
| Urquiza, P | 1 |
| Borges, JI | 1 |
| Lymperopoulos, A | 4 |
| Solesio, ME | 1 |
| Garcia-Garduño, TC | 1 |
| Padilla-Gutierrez, JR | 1 |
| Cambrón-Mora, D | 1 |
| Valle, Y | 1 |
| Mandal, R | 1 |
| Kaur, S | 1 |
| Gupta, VK | 1 |
| Joshi, A | 1 |
| Joseph, JJ | 1 |
| Echouffo-Tcheugui, JB | 1 |
| Kalyani, RR | 1 |
| Yeh, HC | 1 |
| Bertoni, AG | 1 |
| Effoe, VS | 1 |
| Casanova, R | 1 |
| Sims, M | 1 |
| Wu, WC | 1 |
| Wand, GS | 1 |
| Correa, A | 1 |
| Golden, SH | 1 |
| Williams, SA | 1 |
| Murthy, AC | 1 |
| DeLisle, RK | 1 |
| Hyde, C | 1 |
| Malarstig, A | 1 |
| Ostroff, R | 1 |
| Weiss, SJ | 1 |
| Segal, MR | 1 |
| Ganz, P | 1 |
| Hillaert, MA | 2 |
| den Ruijter, HM | 1 |
| Hoefer, IE | 1 |
| Lentjes, EG | 1 |
| de Borst, GJ | 1 |
| de Vries, JPM | 1 |
| Doevendans, PA | 2 |
| Pasterkamp, G | 1 |
| Timmers, L | 1 |
| Docherty, KF | 1 |
| Jhund, PS | 1 |
| Cannone, V | 1 |
| Buglioni, A | 1 |
| Sangaralingham, SJ | 1 |
| Scott, C | 1 |
| Bailey, KR | 1 |
| Rodeheffer, R | 1 |
| Redfield, MM | 1 |
| Sarzani, R | 1 |
| Burnett, JC | 1 |
| Resic, N | 1 |
| Durak-Nalbantic, A | 1 |
| Dzubur, A | 1 |
| Begic, A | 1 |
| Begic, E | 1 |
| Mignano, A | 1 |
| Pitruzzella, V | 1 |
| Arnone, G | 1 |
| Arnone, MT | 1 |
| Rotolo, A | 1 |
| Assennato, P | 1 |
| Novo, G | 1 |
| Corrado, E | 1 |
| Novo, S | 1 |
| Bathgate-Siryk, A | 2 |
| Dabul, S | 2 |
| Pandya, K | 1 |
| Walklett, K | 2 |
| Rengo, G | 3 |
| Cannavo, A | 1 |
| De Lucia, C | 1 |
| Liccardo, D | 1 |
| Gao, E | 1 |
| Leosco, D | 1 |
| Koch, WJ | 3 |
| Ozaki, Y | 2 |
| Imanishi, T | 2 |
| Tanimoto, T | 2 |
| Teraguchi, I | 1 |
| Nishiguchi, T | 1 |
| Orii, M | 2 |
| Shiono, Y | 2 |
| Shimamura, K | 2 |
| Yamano, T | 1 |
| Ino, Y | 2 |
| Yamaguchi, T | 1 |
| Kubo, T | 1 |
| Akasaka, T | 2 |
| Chen, B | 1 |
| Lu, D | 1 |
| Fu, Y | 1 |
| Zhang, J | 1 |
| Huang, X | 1 |
| Cao, S | 1 |
| Xu, D | 1 |
| Bin, J | 1 |
| Kitakaze, M | 1 |
| Huang, Q | 1 |
| Liao, Y | 1 |
| Hu, J | 1 |
| Li, Y | 1 |
| Cheng, W | 1 |
| Yang, Z | 1 |
| Wang, F | 1 |
| Lv, P | 1 |
| Niu, C | 1 |
| Hou, Y | 1 |
| Yan, Y | 1 |
| Ge, J | 1 |
| Rafatian, N | 1 |
| Westcott, KV | 2 |
| White, RA | 3 |
| Leenen, FH | 6 |
| Sturchler, E | 1 |
| Garcia, D | 1 |
| McDonald, P | 1 |
| Lemarié, J | 1 |
| Mandry, D | 1 |
| Juillière, Y | 1 |
| Moulin, F | 1 |
| Lemoine, S | 1 |
| Selton-Suty, C | 1 |
| Gao, Y | 1 |
| Gao, J | 1 |
| Chen, C | 1 |
| Wang, H | 1 |
| Guo, J | 1 |
| Wu, R | 1 |
| Alexandre, J | 1 |
| Hof, T | 1 |
| Puddu, PE | 1 |
| Rouet, R | 1 |
| Guinamard, R | 1 |
| Manrique, A | 1 |
| Beygui, F | 5 |
| Sallé, L | 1 |
| Milliez, P | 1 |
| Xanthakis, V | 1 |
| Enserro, DM | 1 |
| Larson, MG | 1 |
| Wollert, KC | 1 |
| Januzzi, JL | 1 |
| Levy, D | 1 |
| Aragam, J | 1 |
| Benjamin, EJ | 1 |
| Wang, TJ | 1 |
| Mitchell, GF | 1 |
| Vasan, RS | 1 |
| Pitts, R | 1 |
| Gunzburger, E | 1 |
| Ballantyne, CM | 1 |
| Barter, PJ | 1 |
| Kallend, D | 1 |
| Leiter, LA | 1 |
| Leitersdorf, E | 1 |
| Nicholls, SJ | 1 |
| Shah, PK | 1 |
| Tardif, JC | 2 |
| Olsson, AG | 1 |
| McMurray, JJ | 2 |
| Kittelson, J | 1 |
| Schwartz, GG | 1 |
| Huang, BS | 3 |
| Ahmad, M | 2 |
| Tan, J | 1 |
| Jeng, AY | 1 |
| Palmer, BR | 2 |
| Pilbrow, AP | 2 |
| Frampton, CM | 2 |
| Yandle, TG | 2 |
| Skelton, L | 2 |
| Nicholls, MG | 2 |
| Richards, AM | 3 |
| Pitt, B | 4 |
| Wu, ZL | 1 |
| Xu, DL | 1 |
| Deng, LH | 1 |
| Wen, YW | 1 |
| Huang, P | 1 |
| Bai, SC | 1 |
| Su, L | 1 |
| Montalescot, G | 4 |
| Vicaut, E | 2 |
| Rouanet, S | 1 |
| Van Belle, E | 3 |
| Baulac, C | 1 |
| Degrandsart, A | 1 |
| Dallongeville, J | 2 |
| Mihailidou, AS | 1 |
| Loan Le, TY | 1 |
| Mardini, M | 1 |
| Funder, JW | 2 |
| Martinez, FA | 1 |
| Ecollan, P | 1 |
| Machecourt, J | 1 |
| Zincarelli, C | 1 |
| Kim, J | 1 |
| Vergaro, G | 1 |
| Emdin, M | 1 |
| Iervasi, A | 1 |
| Zyw, L | 1 |
| Gabutti, A | 1 |
| Poletti, R | 1 |
| Mammini, C | 1 |
| Giannoni, A | 1 |
| Fontana, M | 1 |
| Passino, C | 1 |
| Boccanelli, A | 1 |
| Agostoni, P | 1 |
| Ivanes, F | 1 |
| Susen, S | 1 |
| Mouquet, F | 1 |
| Pigny, P | 1 |
| Cuilleret, F | 1 |
| Sautière, K | 1 |
| Collet, JP | 2 |
| Hennache, B | 1 |
| Ennezat, PV | 1 |
| Juthier, F | 1 |
| Richard, F | 1 |
| Jude, B | 1 |
| Bertrand, M | 1 |
| Mill, JG | 1 |
| Stefanon, I | 1 |
| dos Santos, L | 1 |
| Baldo, MP | 1 |
| Weir, RA | 1 |
| Tsorlalis, IK | 1 |
| Steedman, T | 1 |
| Dargie, HJ | 1 |
| Fraser, R | 1 |
| Connell, JM | 1 |
| He, BJ | 1 |
| Joiner, ML | 1 |
| Singh, MV | 1 |
| Luczak, ED | 1 |
| Swaminathan, PD | 1 |
| Koval, OM | 1 |
| Kutschke, W | 1 |
| Allamargot, C | 1 |
| Yang, J | 1 |
| Guan, X | 1 |
| Zimmerman, K | 1 |
| Grumbach, IM | 1 |
| Weiss, RM | 1 |
| Spitz, DR | 1 |
| Sigmund, CD | 1 |
| Blankesteijn, WM | 1 |
| Heymans, S | 1 |
| Mohler, PJ | 1 |
| Anderson, ME | 1 |
| Ohtani, K | 1 |
| Usui, S | 1 |
| Kaneko, S | 1 |
| Takashima, S | 1 |
| Kitano, K | 1 |
| Yamamoto, K | 1 |
| Okajima, M | 1 |
| Furusho, H | 1 |
| Takamura, M | 1 |
| Chabot, A | 1 |
| Jiang, BH | 1 |
| Shi, Y | 1 |
| Dupuis, J | 1 |
| Kashiwagi, M | 1 |
| Tsujioka, H | 1 |
| Sougawa, H | 1 |
| Ishibashi, K | 1 |
| Komukai, K | 1 |
| Kitabata, H | 1 |
| Butler, J | 1 |
| Ezekowitz, JA | 1 |
| Collins, SP | 1 |
| Givertz, MM | 1 |
| Teerlink, JR | 1 |
| Walsh, MN | 1 |
| Albert, NM | 1 |
| Westlake Canary, CA | 1 |
| Carson, PE | 1 |
| Colvin-Adams, M | 1 |
| Fang, JC | 1 |
| Hernandez, AF | 1 |
| Hershberger, RE | 1 |
| Katz, SD | 1 |
| Rogers, JG | 1 |
| Spertus, JA | 1 |
| Stevenson, WG | 1 |
| Sweitzer, NK | 1 |
| Tang, WH | 1 |
| Stough, WG | 1 |
| Starling, RC | 1 |
| Yano, H | 1 |
| Hibi, K | 1 |
| Nozawa, N | 1 |
| Ozaki, H | 1 |
| Kusama, I | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Tsukahara, K | 1 |
| Okuda, J | 1 |
| Morita, S | 1 |
| Umemura, S | 1 |
| Kimura, K | 1 |
| Galuppo, P | 2 |
| Bauersachs, J | 2 |
| Noda, K | 1 |
| Kobara, M | 1 |
| Hamada, J | 1 |
| Yoshifuji, Y | 1 |
| Shiraishi, T | 1 |
| Tanaka, T | 1 |
| Wang, J | 1 |
| Toba, H | 1 |
| Nakata, T | 1 |
| Marc, Y | 1 |
| Llorens-Cortes, C | 1 |
| Sanderson, JE | 1 |
| Cittadini, A | 1 |
| Casaburi, C | 1 |
| Monti, MG | 1 |
| Di Gianni, A | 1 |
| Serpico, R | 1 |
| Scherillo, G | 1 |
| Saldamarco, L | 1 |
| Vanasia, M | 1 |
| Saccà, L | 1 |
| Jessup, M | 1 |
| Casal, AJ | 1 |
| Silvestre, JS | 4 |
| Delcayre, C | 4 |
| Capponi, AM | 1 |
| Sheppard, KE | 1 |
| Jołda-Mydłowska, B | 1 |
| Salomon, P | 1 |
| GARAGNANI, A | 2 |
| SURIANI, L | 3 |
| BRILLANTE, C | 3 |
| RAPINO, P | 1 |
| RAVENNI, G | 1 |
| RUBEGNI, M | 1 |
| DI PERRI, T | 1 |
| CHIERICI, F | 1 |
| MANZINI, E | 1 |
| WEXLER, BC | 3 |
| KITTINGER, GW | 1 |
| Yakobson, GS | 1 |
| Antonov, AR | 2 |
| Efremov, AV | 2 |
| Makhanova, NA | 1 |
| Shmerling, MD | 1 |
| Maksimov, VF | 1 |
| Korostyshevskaya, IM | 1 |
| Yakobson, MG | 1 |
| Christ, M | 1 |
| Grimm, W | 1 |
| Maisch, B | 2 |
| Rebsamen, MC | 1 |
| Perrier, E | 1 |
| Gerber-Wicht, C | 1 |
| Benitah, JP | 1 |
| Lang, U | 1 |
| Rudolph, AE | 1 |
| Rocha, R | 1 |
| McMahon, EG | 2 |
| Lacour, C | 1 |
| Roccon, A | 1 |
| Galindo, G | 1 |
| Canals, F | 1 |
| Hogie, M | 1 |
| Segondy, D | 1 |
| Briand, D | 1 |
| Roque, C | 1 |
| Herbert, JM | 1 |
| Nisato, D | 1 |
| Krum, H | 1 |
| Liew, D | 1 |
| Rungwerth, K | 1 |
| Schindler, U | 1 |
| Gerl, M | 1 |
| Schäfer, S | 1 |
| Licher, T | 1 |
| Busch, AE | 1 |
| Ruetten, H | 1 |
| Nakamura, R | 1 |
| Kato, J | 1 |
| Kitamura, K | 1 |
| Onitsuka, H | 1 |
| Imamura, T | 1 |
| Cao, Y | 1 |
| Marutsuka, K | 1 |
| Asada, Y | 1 |
| Kangawa, K | 1 |
| Eto, T | 1 |
| Tan, LB | 1 |
| Schlosshan, D | 1 |
| Barker, D | 1 |
| Saito, Y | 1 |
| Lal, A | 2 |
| Veinot, JP | 2 |
| Bos, R | 1 |
| Mougenot, N | 1 |
| Findji, L | 1 |
| Médiani, O | 1 |
| Vanhoutte, PM | 1 |
| Lechat, P | 1 |
| Heinzl, S | 1 |
| Struthers, AD | 1 |
| Katada, J | 1 |
| Meguro, T | 1 |
| Saito, H | 1 |
| Ohashi, A | 1 |
| Anzai, T | 1 |
| Ogawa, S | 1 |
| Yoshikawa, T | 1 |
| Ganten, D | 1 |
| Westendorp, B | 2 |
| Schoemaker, RG | 2 |
| Buikema, H | 2 |
| Boomsma, F | 2 |
| van Veldhuisen, DJ | 1 |
| van Gilst, WH | 2 |
| Sun, Y | 4 |
| Weber, KT | 5 |
| Kessler-Icekson, G | 1 |
| Schlesinger, H | 1 |
| Freimann, S | 1 |
| Kessler, E | 1 |
| Chai, W | 1 |
| Garrelds, IM | 1 |
| de Vries, R | 1 |
| Danser, AH | 1 |
| Kalantarinia, K | 1 |
| Okusa, MD | 1 |
| Cohn, JN | 1 |
| Colucci, W | 1 |
| Collins, RP | 1 |
| Troughton, RW | 1 |
| Cameron, VA | 2 |
| Tingberg, E | 1 |
| Roijer, A | 1 |
| Thilen, U | 1 |
| Ohlin, H | 1 |
| Benoliel, JJ | 1 |
| Vignolles, N | 1 |
| Dumaine, R | 1 |
| Barthélémy, O | 1 |
| Urabe, A | 1 |
| Izumi, T | 1 |
| Abe, Y | 1 |
| Taniguchi, I | 1 |
| Mochizuki, S | 1 |
| Calhoun, DA | 1 |
| Brandes, RP | 1 |
| Fraccarollo, D | 1 |
| Schraut, S | 1 |
| Kneitz, S | 1 |
| van Rooijen, N | 1 |
| Ertl, G | 1 |
| Wenting, GJ | 1 |
| Man in't veld, AJ | 1 |
| Woittiez, AJ | 1 |
| Laird-Meeter, K | 1 |
| Simoons, ML | 1 |
| Hugenholtz, PG | 1 |
| Schalekamp, MA | 1 |
| Michorowski, B | 1 |
| Ceremuzyński, L | 3 |
| Prys-Roberts, C | 1 |
| Webster, J | 1 |
| Petrie, JC | 1 |
| McLean, I | 1 |
| Hawksworth, GM | 1 |
| Iakobson, MG | 3 |
| Kuimov, AD | 3 |
| Sorokin, AS | 2 |
| Gizatulin, ZIa | 1 |
| Golikov, AP | 3 |
| Ivleva, VI | 2 |
| Malaev, MG | 2 |
| Laragh, JH | 2 |
| Raman, VK | 1 |
| Lee, YA | 1 |
| Lindpaintner, K | 1 |
| Reed, S | 1 |
| Greene, P | 1 |
| Ryan, T | 1 |
| Cerimele, B | 1 |
| Schwertschlag, U | 1 |
| Weinberger, M | 1 |
| Voelker, J | 1 |
| Brilla, CG | 1 |
| Rupp, H | 1 |
| Funck, R | 1 |
| Zhou, G | 1 |
| Jugdutt, BI | 1 |
| Khan, MI | 1 |
| Jugdutt, SJ | 1 |
| Blinston, GE | 1 |
| Rouleau, JL | 3 |
| Packer, M | 2 |
| Moyé, L | 2 |
| de Champlain, J | 3 |
| Bichet, D | 3 |
| Klein, M | 2 |
| Rouleau, JR | 1 |
| Sussex, B | 2 |
| Arnold, JM | 2 |
| Sestier, F | 2 |
| Dagenais, GR | 1 |
| Bellone, P | 2 |
| Derchi, G | 2 |
| Tommasini, G | 2 |
| Biorci, ML | 2 |
| Randazzo, M | 2 |
| Primarolo, P | 2 |
| Vecchio, C | 2 |
| Pouleur, H | 1 |
| Sigurdsson, A | 2 |
| Held, P | 2 |
| Swedberg, K | 2 |
| Kyriakidis, M | 1 |
| Petropoulakis, P | 1 |
| Aspiotis, N | 1 |
| Tselika, C | 1 |
| Antonopoulos, A | 1 |
| Marakas, S | 1 |
| Toutouzas, P | 1 |
| Wall, B | 1 |
| Borghi, C | 1 |
| Boschi, S | 1 |
| Ambrosioni, E | 1 |
| Melandri, G | 1 |
| Branzi, A | 1 |
| Magnani, B | 1 |
| González-Fernández, RA | 1 |
| Altieri, PI | 1 |
| Lugo, JE | 1 |
| Fernández-Martínez, J | 1 |
| Fujiwara, M | 1 |
| Asakuma, S | 1 |
| Nakamura, T | 1 |
| Nakamura, K | 1 |
| Iwasaki, T | 1 |
| Cleutjens, JP | 1 |
| Tanabe, K | 1 |
| Suzuki, N | 1 |
| Osada, N | 1 |
| Yamamoto, A | 1 |
| Nakayama, M | 1 |
| Yokoyama, Y | 1 |
| Sakakibara, M | 1 |
| Itoh, H | 1 |
| Murayama, M | 1 |
| Yamada, S | 1 |
| Yamasaki, H | 1 |
| Uusimaa, P | 1 |
| Risteli, J | 1 |
| Niemelä, M | 1 |
| Lumme, J | 1 |
| Ikäheimo, M | 1 |
| Jounela, A | 1 |
| Peuhkurinen, K | 1 |
| Budaj, A | 1 |
| Herbaczyńska-Cedro, K | 1 |
| Kokot, F | 1 |
| Vantrimpont, P | 1 |
| Ciampi, A | 1 |
| Harel, F | 1 |
| Moyé, LA | 1 |
| Pfeffer, M | 1 |
| Harrington, JL | 1 |
| Farley, DR | 1 |
| van Heerden, JA | 1 |
| Ramin, KD | 1 |
| Heymes, C | 2 |
| Oubénaïssa, A | 3 |
| Robert, V | 3 |
| Aupetit-Faisant, B | 2 |
| Carayon, A | 2 |
| Swynghedauw, B | 3 |
| Hautanen, A | 1 |
| Toivanen, P | 1 |
| Mänttäri, M | 1 |
| Tenkanen, L | 1 |
| Kupari, M | 1 |
| Manninen, V | 1 |
| Kayes, KM | 1 |
| Rosenfeld, S | 1 |
| White, PC | 1 |
| Rademaker, MT | 1 |
| Charles, CJ | 1 |
| Espiner, EA | 1 |
| Pemberton, CJ | 1 |
| Markel', AL | 1 |
| Petrova, GV | 1 |
| Iakobson, GS | 2 |
| Garnier, A | 1 |
| Cailmail, S | 1 |
| Tatara, E | 1 |
| Pasquale, PD | 1 |
| Stefano, GD | 1 |
| Paterna, S | 1 |
| Williams, G | 1 |
| Remme, W | 1 |
| Martinez, F | 1 |
| Lopez-Sendon, J | 1 |
| Neaton, J | 1 |
| Roniker, B | 1 |
| Hurley, S | 1 |
| Burns, D | 1 |
| Bittman, R | 1 |
| Kleiman, J | 1 |
| Kikuchi, M | 1 |
| Nakamura, M | 2 |
| Suzuki, T | 1 |
| Sato, M | 1 |
| Takino, T | 1 |
| Hiramori, K | 1 |
| Hayashi, M | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Maeda, K | 1 |
| Mabuchi, N | 1 |
| Tsutsui, T | 1 |
| Matsui, T | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Yamamoto, T | 1 |
| Horie, H | 1 |
| Ohnishi, M | 1 |
| Kinoshita, M | 1 |
| Remme, WJ | 1 |
| Xiu, JC | 1 |
| Wu, P | 1 |
| Xu, JP | 1 |
| Guo, Z | 1 |
| Lai, W | 1 |
| Zhang, Y | 1 |
| Li, S | 1 |
| Liu, Y | 1 |
| Abenhaim, L | 1 |
| Kuchel, O | 1 |
| Drozdova, ES | 2 |
| Salem, S | 1 |
| Rossel's, AN | 1 |
| Orlov, AI | 1 |
| Bogdanovich, NK | 1 |
| Bobkov, AI | 1 |
| Zysko, AP | 1 |
| Belianin, VI | 1 |
| Stepanova, IP | 1 |
| Mrochek, AG | 1 |
| Sytyĭ, VP | 1 |
| Livshits, IB | 1 |
| Sherstiuk, GV | 1 |
| Alekseeva, DD | 1 |
| Ivanchikov, VI | 1 |
| Kripskaia, NE | 1 |
| Jiang, M | 1 |
| Volpe, M | 1 |
| Lembo, G | 1 |
| De Luca, N | 1 |
| Lamenza, F | 1 |
| Tritto, C | 1 |
| Ricciardelli, B | 1 |
| Molaro, M | 1 |
| De Campora, P | 1 |
| Condorelli, G | 1 |
| Rendina, V | 1 |
| Gutierrez-Marcos, FM | 1 |
| Fernandez-Cruz, A | 1 |
| Gutkowska, J | 1 |
| Herrero, C | 1 |
| Blesa, A | 1 |
| Estrada, V | 1 |
| Loscos, C | 1 |
| López-Novoa, JM | 1 |
| Prachar, H | 1 |
| Hirvonen, T | 1 |
| Remes, J | 1 |
| Mustonen, J | 1 |
| Tikkanen, I | 1 |
| Tenhunen, M | 1 |
| Pyörälä, K | 1 |
| De Marzio, P | 1 |
| Morelli, S | 1 |
| Ferri, C | 1 |
| Cacciafesta, M | 1 |
| Bellini, C | 1 |
| Perrone, A | 1 |
| Aguglia, F | 1 |
| Santucci, A | 1 |
| Balsano, F | 1 |
| Kageyama, Y | 1 |
| Suzuki, H | 1 |
| Saruta, T | 1 |
| Markuljak, I | 1 |
| Kvĕtenský, J | 1 |
| Funiak, S | 1 |
| Záhradný, V | 1 |
| Vladár, L | 1 |
| Vaughan, DE | 1 |
| Lamas, GA | 1 |
| Pfeffer, MA | 1 |
| Fontana, F | 3 |
| Bernardi, P | 5 |
| Spagnolo, N | 3 |
| Capelli, M | 3 |
| Arakawa, N | 1 |
| Kato, M | 1 |
| Zhao, L | 1 |
| Meissner, D | 1 |
| Hubl, W | 1 |
| Schmidt, PK | 1 |
| Zabello, IN | 1 |
| Hodsman, GP | 1 |
| Kohzuki, M | 1 |
| Howes, LG | 1 |
| Sumithran, E | 1 |
| Tsunoda, K | 1 |
| Johnston, CI | 1 |
| McAlpine, HM | 1 |
| Cobbe, SM | 1 |
| Bayliss, J | 1 |
| Canepa-Anson, R | 1 |
| Norell, M | 1 |
| Poole-Wilson, P | 1 |
| Sutton, G | 1 |
| Leor, R | 1 |
| Stalnikowicz, R | 1 |
| Koshu, M | 1 |
| Sugimoto, T | 1 |
| Terada, Y | 1 |
| Uraoka, T | 1 |
| Malaia, IT | 1 |
| Lazareva, SA | 1 |
| Brunner, HR | 1 |
| Baer, L | 1 |
| Newton, MA | 1 |
| Goodwin, FT | 1 |
| Krakoff, LR | 1 |
| Bard, RH | 1 |
| Bühler, FR | 1 |
| Wood, JE | 1 |
| Arora, RB | 4 |
| Judd, JT | 2 |
| Lutmer, RJ | 1 |
| Saroff, J | 2 |
| Omel'chenko, AP | 1 |
| Goncharova, DN | 1 |
| Weil, MH | 1 |
| Shubin, H | 1 |
| Gupta, SK | 1 |
| Sharma, RC | 1 |
| Siddiqui, HH | 2 |
| Lutmer, RF | 1 |
| Korochkin, IM | 1 |
| Matveeva, IV | 1 |
| Korolova, SA | 1 |
| Lenzi, S | 1 |
| Descovich, GC | 2 |
| Siemon, G | 1 |
| Chazov, EI | 1 |
| Gritti, FM | 1 |
| Montini, T | 1 |
| Perrini, M | 1 |
| Piliego, N | 1 |
| Rossini, P | 1 |
| Del Zotti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579] | Phase 4 | 8,000 participants (Anticipated) | Interventional | 2023-04-16 | Enrolling by invitation | ||
| Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study (SomaSignal Study)[NCT04836117] | 200 participants (Anticipated) | Interventional | 2021-08-12 | Recruiting | |||
| Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjec[NCT00134264] | Phase 3 | 15,067 participants (Actual) | Interventional | 2004-07-31 | Terminated | ||
| A Safety and Feasibility Study of Water-only Fasting and Refeeding for Treatment of Stage 1 and 2 Hypertensive Patients[NCT04515095] | 30 participants (Actual) | Interventional | 2020-08-16 | Completed | |||
| Multiparametric Study of Cardiac Remodeling After Myocardial Infarction Revascularized in Acute Phase : Relation With the Serum Concentrations in Aldosterone[NCT01109225] | 145 participants (Actual) | Interventional | 2010-04-27 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome[NCT00658515] | Phase 3 | 15,871 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL[NCT01059136] | Phase 3 | 1,603 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study[NCT00132093] | Phase 4 | 100 participants | Interventional | 2005-04-30 | Completed | ||
| Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression[NCT01889992] | Phase 1 | 42 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to PI left University and project not continued) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00658515)
Timeframe: At 53 Months
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Dalcetrapib (RO4607381) | 44.96 |
| Placebo | 15.60 |
(NCT00658515)
Timeframe: Throughout Study, up to 53 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Dalcetrapib (RO4607381) | 226 |
| Placebo | 229 |
Number of cardiovascular events per patient per year (NCT00658515)
Timeframe: From date of randomization to first event up to 48 months
| Intervention | Event per Patient Years of Followup (Number) |
|---|---|
| Dalcetrapib (RO4607381) | 0.034050 |
| Placebo | 0.032759 |
34 reviews available for aldosterone and Myocardial Infarction
| Article | Year |
|---|---|
Aldosterone and cardiovascular diseases.
Topics: Aldosterone; Atherosclerosis; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Humans; H | 2023 |
Aldosterone receptor antagonists.
Topics: Aldosterone; Blood Pressure; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagon | 2021 |
The role of aldosterone inhibitors in cardiac ischemia-reperfusion injury.
Topics: Aldosterone; Animals; Cardiotonic Agents; Clinical Trials as Topic; Disease Models, Animal; Heart Ve | 2021 |
Impact of Aldosterone on the Failing Myocardium: Insights from Mitochondria and Adrenergic Receptors Signaling and Function.
Topics: Aldosterone; Animals; Heart Failure; Humans; Mitochondria, Heart; Myocardial Infarction; Myocardium; | 2021 |
RAAS: A Convergent Player in Ischemic Heart Failure and Cancer.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Myocar | 2021 |
Brain renin-angiotensin-aldosterone system and ventricular remodeling after myocardial infarct: a review.
Topics: Aldosterone; Animals; Apoptosis; Brain; Humans; Myocardial Infarction; Myocarditis; Myocytes, Cardia | 2009 |
Remodeling in the ischemic heart: the stepwise progression for heart failure.
Topics: Adrenergic Neurons; Aldosterone; Angiotensins; Apoptosis; Arrhythmias, Cardiac; Heart; Heart Failure | 2011 |
Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
Topics: Aldosterone; Genetic Techniques; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Ant | 2012 |
Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adrenal Cortex Hormones; Aldosterone; Animals; Binding Sites; | 2003 |
Aldosterone blockade in patients with systolic left ventricular dysfunction.
Topics: Aldosterone; Eplerenone; Forecasting; Heart Failure; Humans; Hypercholesterolemia; Hypertension; Mal | 2003 |
[Significance of aldosterone antagonist therapy].
Topics: Aldosterone; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dr | 2004 |
Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Digoxin; Enzyme Inhibitors; Eplerenone; Female; Human | 2004 |
Aldosterone target organ protection by eplerenone.
Topics: Aldosterone; Blood Vessels; Brain; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Hype | 2004 |
Eplerenone in the treatment of chronic heart failure.
Topics: Aldosterone; Chronic Disease; Clinical Trials as Topic; Eplerenone; Heart Failure; Humans; Mineraloc | 2004 |
Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy.
Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; R | 2004 |
[Therapeutic application of ANP: past and future].
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Cardiopulmonary Bypass; Chronic Disease; Cyclic GMP | 2004 |
Pathophysiology of heart failure following myocardial infarction.
Topics: Aldosterone; Angiotensins; Fibrosis; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardia | 2005 |
The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascu | 2006 |
Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
Topics: Aldosterone; Animals; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Ventric | 2006 |
Pathophysiology of hypertension and ischemic heart disease.
Topics: Adult; Aldosterone; Animals; Cardiomegaly; Coronary Circulation; Coronary Disease; Endocardium; Hear | 1980 |
Hormonal and metabolic reactions evoked by acute myocardial infarction.
Topics: Acute Disease; Adrenergic Fibers; Aldosterone; Angina Pectoris, Variant; Animals; Catecholamines; Ca | 1981 |
Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).
Topics: Aldosterone; Animals; Blood Pressure; Cardiovascular Diseases; Cerebrovascular Disorders; Electrolyt | 1995 |
The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; An | 1995 |
Pharmacological modulation of cardiac fibroblast function.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dilated; Collagen; E | 1995 |
Role of neurohormones in ventricular adaptation and failure.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Animals; Cardiomegaly; Disease Models, Anima | 1994 |
Tissue angiotensin II and myocardial infarction.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Col | 1996 |
Structural remodeling of the infarcted rat heart.
Topics: Aldosterone; Angiotensin II; Animals; Collagen; Fibrosis; Humans; Metalloendopeptidases; Myocardial | 1996 |
Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Endomyocardial Fibro | 1998 |
Cardiac aldosterone production and ventricular remodeling.
Topics: Aldosterone; Animals; Fibrosis; Humans; Myocardial Infarction; Myocardium; Ventricular Remodeling | 2000 |
Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Blood Vessels; Cardiovasc | 2000 |
Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
Topics: Aldosterone; Animals; Cardiovascular System; Clinical Trials as Topic; Endothelium, Vascular; Eplere | 2001 |
[Prostaglandins, kallikrein-kinin and dopamine. Practical implications of this vasodilator-natriuretic system].
Topics: Aldosterone; Angiotensin II; Anti-Inflammatory Agents; Arachidonic Acids; Bartter Syndrome; Bradykin | 1979 |
The cardiovascular effects of oral contraceptives.
Topics: Aldosterone; Angiotensin II; Blood Coagulation; Blood Flow Velocity; Blood Vessels; Cardiovascular S | 1972 |
Shock following acute myocardial infarction. Current understanding of hemodynamic mechanisms.
Topics: Acidosis; Aldosterone; Animals; Arrhythmias, Cardiac; Arteries; Blood Flow Velocity; Blood Pressure; | 1968 |
21 trials available for aldosterone and Myocardial Infarction
| Article | Year |
|---|---|
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Chol | 2018 |
Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction.
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme In | 2014 |
Usefulness of Speckle-Tracking Imaging for Right Ventricular Assessment after Acute Myocardial Infarction: A Magnetic Resonance Imaging/Echocardiographic Comparison within the Relation between Aldosterone and Cardiac Remodeling after Myocardial Infarction
Topics: Aldosterone; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Humans; Magnetic Reso | 2015 |
Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial.
Topics: Aged; Aldosterone; Canrenoic Acid; Dose-Response Relationship, Drug; Electrocardiography; Female; Fo | 2010 |
Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction.
Topics: Aldosterone; Biomarkers; Double-Blind Method; Echocardiography; Electrocardiography; Eplerenone; Fem | 2011 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2012 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
Neurohumoral changes in patients with left ventricular dysfunction following acute myocardial infarction and the effect of nitrate therapy: a randomized, double-blind, placebo-controlled long-term study.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Double-Blind Method; Echocardiography; Female; | 2006 |
The renin angiotensin aldosterone system and frusemide response in congestive heart failure.
Topics: Administration, Oral; Aged; Aldosterone; Captopril; Cross-Over Studies; Drug Therapy, Combination; F | 1995 |
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
Topics: Aged; Aldosterone; Analysis of Variance; Arginine Vasopressin; Atrial Natriuretic Factor; Canada; Ca | 1994 |
Activation of neurohumoral systems in postinfarction left ventricular dysfunction.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Cardiac Output, Low; Dopamine; Female; Humans; Male; M | 1993 |
Neurohormonal effects of early treatment with enalapril after acute myocardial infarction and the impact on left ventricular remodelling.
Topics: Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Dopamine; Double-Blind Method; Enalapril; Ep | 1993 |
Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Dose-Response Rela | 1993 |
Effects of enalapril on ventricular volumes and neurohumoral status after inferior wall myocardial infarction.
Topics: Aged; Aldosterone; Angiotensin II; Cardiac Volume; Double-Blind Method; Enalapril; Female; Humans; M | 1993 |
Effects of cilazapril on exercise tolerance in the chronic phase of acute myocardial infarction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Ca | 1996 |
Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Epinephrine; Female; Humans; Male; | 1998 |
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Captopril; Female; | 1998 |
Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction.
Topics: Adult; Aldosterone; Alleles; Baroreflex; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; C | 1999 |
Effect of enalapril on plasma atrial natriuretic peptide in late recovery phase of acute myocardial infarction.
Topics: Aldosterone; Atrial Natriuretic Factor; Double-Blind Method; Enalapril; Epinephrine; Female; Humans; | 1991 |
Renal, hormonal, and hemodynamic effects of low-dose infusion of atrial natriuretic factor in acute myocardial infarction.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Diuretics; Female; Hemodynamics; Humans; Infusions, In | 1990 |
The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin.
Topics: Aged; Aldosterone; Captopril; Cardiac Output; Cardiomyopathy, Dilated; Coronary Disease; Double-Blin | 1986 |
137 other studies available for aldosterone and Myocardial Infarction
| Article | Year |
|---|---|
Primary aldosteronism presenting as embolic myocardial infarction.
Topics: Adrenal Glands; Aldosterone; Arrhythmias, Cardiac; Embolism; Female; Humans; Hyperaldosteronism; Hyp | 2022 |
Transient gene therapy using cell cycle factors reverses renin-angiotensin-aldosterone system activation in heart failure rat model.
Topics: Aldosterone; Animals; Cell Cycle; Heart Failure; Kidney; Myocardial Infarction; Rats; Renin; Renin-A | 2023 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Topics: Aldosterone; Animals; Arginine Vasopressin; Collagen Type I; Endothelial Cells; Fibrosis; Heart; Myo | 2022 |
Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction.
Topics: Aldosterone; Antihypertensive Agents; Enzyme Inhibitors; Heart Failure; Humans; Myocardial Infarctio | 2023 |
Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: The REMI study.
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; ST Elevation Myocardial Infarction; Strok | 2023 |
An implantable system for long-term assessment of atrial fibrillation substrate in unanesthetized rats exposed to underlying pathological conditions.
Topics: Aldosterone; Animals; Atrial Fibrillation; Disease Models, Animal; Electrodes, Implanted; Fibrosis; | 2020 |
VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism.
Topics: Aldosterone; Animals; Apoptosis; Calcium Signaling; Cytochromes c; Disease Models, Animal; Fibrosis; | 2020 |
Effect of Guanxin V in animal model of acute myocardial infarction.
Topics: Aldosterone; Animals; Apoptosis; Cricetinae; Disease Models, Animal; Drugs, Chinese Herbal; Humans; | 2021 |
Heavy metals controlling cardiovascular diseases risk factors in myocardial infarction patients in critically environmentally heavy metal-polluted steel industrial town Mandi-Gobindgarh (India).
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; C-Reactive Protein; Cardiovascular Diseases; China; Choles | 2022 |
Aldosterone, Renin, Cardiovascular Events, and All-Cause Mortality Among African Americans: The Jackson Heart Study.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Black or African American; Body Mass Index; Cardiovascu | 2017 |
Renin and aldosterone are not associated with vulnerable plaque characteristics in patients with carotid artery disease.
Topics: Aged; Aldosterone; Biomarkers; Carotid Artery Diseases; Chi-Square Distribution; Endarterectomy, Car | 2018 |
Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?
Topics: Aldosterone; Data Analysis; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; S | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population.
Topics: Aged; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Cholesterol, L | 2018 |
Serum Aldosterone as Predictor of Progression of Coronary Heart Disease in Patients Without Signs of Heart Failure After Acute Myocardial Infarction.
Topics: Aged; Aldosterone; Biomarkers; Coronary Disease; Disease Progression; Female; Follow-Up Studies; Hum | 2018 |
Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aldosterone; Arrhythmias, Cardiac; Biomarkers; Chi | 2014 |
Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.
Topics: Adrenal Glands; Aldosterone; Animals; Apoptosis; Arrestins; beta-Arrestin 1; beta-Arrestin 2; beta-A | 2014 |
Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Cells, Cul | 2014 |
A comparison of the efficacy of surgical renal denervation and pharmacologic therapies in post-myocardial infarction heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angioten | 2014 |
Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade.
Topics: Aldosterone; Animals; Apoptosis; Caspase 3; Disease Models, Animal; Eplerenone; Macrophages; Male; M | 2014 |
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; H | 2014 |
Cardioprotective effect of polydatin on ventricular remodeling after myocardial infarction in coronary artery ligation rats.
Topics: Aldosterone; Animals; Antioxidants; Captopril; Collagen; Coronary Occlusion; Coronary Vessels; Endot | 2015 |
Rapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion.
Topics: Aldosterone; Animals; Female; Heart Ventricles; Male; Membrane Potentials; Myocardial Contraction; M | 2015 |
Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community.
Topics: Adult; Aged; Aldosterone; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Female; He | 2016 |
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure.
Topics: Acute Coronary Syndrome; Aged; Aldosterone; Amides; Angina, Unstable; Anticholesteremic Agents; Card | 2017 |
Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction.
Topics: Aldosterone; Animals; Cardiac Catheterization; Corticosterone; Cytochrome P-450 CYP11B2; Disease Mod | 2009 |
Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction.
Topics: Aldosterone; Atrial Natriuretic Factor; Biomarkers; Female; Follow-Up Studies; Hospital Mortality; H | 2008 |
The measurement of plasma aldosterone in patients post-myocardial infarction.
Topics: Aldosterone; Biomarkers; Humans; Myocardial Infarction; Potassium; Receptors, Mineralocorticoid | 2008 |
[Mechanisms of losartan for inhibition of myocardial fibrosis following myocardial infarction in rats].
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Losartan; M | 2008 |
Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans o
Topics: Aldosterone; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Myocardial Infarction; Pr | 2009 |
Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Topics: Aldosterone; Angina, Unstable; Animals; Apoptosis; Dexamethasone; Glucocorticoids; Hormone Antagonis | 2009 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels.
Topics: Adrenal Glands; Aldosterone; Animals; Arrestins; beta-Arrestin 1; beta-Arrestins; Cell Line; Disease | 2011 |
Prognostic value of plasma renin activity in heart failure.
Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2011 |
[The EMPHASIS-HF study].
Topics: Aldosterone; Biomarkers; Canrenone; Cause of Death; Double-Blind Method; Early Termination of Clinic | 2011 |
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.
Topics: Age Factors; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Body Mass Index; Brain Ischemia; C-R | 2012 |
Oxidation of CaMKII determines the cardiotoxic effects of aldosterone.
Topics: Aldosterone; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiotoxins; Cells, Cultu | 2011 |
Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice.
Topics: Aldosterone; Animals; Apoptosis; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; | 2012 |
Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure.
Topics: Aldosterone; Animals; Cell Proliferation; Echocardiography; Heart Failure; Hypertension, Pulmonary; | 2011 |
Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme In | 2012 |
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Eplerenone; Heart; Heart Failure; Ho | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cel | 2012 |
Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction.
Topics: Aldosterone; Angiotensin III; Animals; Baroreflex; Blood Pressure; Brain; Disease Models, Animal; Di | 2013 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure.
Topics: Administration, Oral; Aldosterone; Animals; Canrenone; Collagen; Cyclodextrins; Disease Models, Anim | 2002 |
Aldosterone blockade and heart failure.
Topics: Aldosterone; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial I | 2003 |
Expression and modulation of steroidogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction.
Topics: Aldosterone; Angiotensin II; Animals; Cells, Cultured; Dexamethasone; Gene Expression; Glucocorticoi | 2003 |
[Cytokines and remodeling of the heart in patients with congestive heart failure].
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Cardiomyopathy, Dilated; Catecholam | 2003 |
[Aldosteronuria and blood and urinary electrolyte balance in myocardial infarct in its recent phase].
Topics: Aldosterone; Humans; Myocardial Infarction; Urinary Tract; Water-Electrolyte Balance | 1962 |
[Effect of aldosterone loading on natriuresis in normal subjects and in the post-infarct period].
Topics: Aldosterone; Humans; Myocardial Infarction; Natriuresis | 1962 |
[Behavior of aldosteronuria and natriuria in the immediate post-infarct period].
Topics: Aldosterone; Humans; Myocardial Infarction; Natriuresis | 1962 |
[Pressure of the tissues in various post-infarct complications and under the influence of aldosterone, spirolactone and saline administration].
Topics: Aldosterone; Heart Failure; Humans; Myocardial Infarction; Sodium Chloride; Spironolactone | 1962 |
STEROIDS PRODUCED IN VITRO BY ADRENAL GLANDS OF NORMAL AND ARTERIOSCLEROTIC RATS DURING AND AFTER DRUG-INDUCED MYOCARDIAL NECROSIS.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aldosterone; Arteriosclerosis; Heart Failure; In Vitro Tech | 1965 |
Pathophysiological aspects of experimental myocardial infarction during arterial hypertension.
Topics: Adult; Aldosterone; Animals; Blood Pressure; Case-Control Studies; Disease Models, Animal; Humans; H | 2003 |
Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction.
Topics: Aldosterone; Animals; Biomarkers; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Fibroblasts; Gene | 2004 |
Effects of differential blockade of the renin-angiotensin system in postinfarcted rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2004 |
Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.
Topics: Aldosterone; Animals; C-Reactive Protein; Electrocardiography; Guanidines; Heart Failure; Inflammati | 2004 |
Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats.
Topics: Adrenomedullin; Aldosterone; Animals; Body Weight; Dinoprost; Disease Progression; Drug Evaluation, | 2004 |
Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats.
Topics: Administration, Oral; Aldosterone; Animals; Central Nervous System; Collagen; Epinephrine; Injection | 2004 |
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anim | 2005 |
[Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction].
Topics: Aldosterone; Cardiac Output, Low; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Myocar | 2005 |
Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction.
Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Gene Expression Regulation; Male; Mice; Mice, Knocko | 2005 |
Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
Topics: Aldosterone; Angiotensinogen; Animals; Animals, Genetically Modified; Brain; Cell Size; Fibronectins | 2005 |
Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Endothelium, Vascular; Hypertrophy, | 2006 |
Animal models of cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Diseases; | 2005 |
Expression of procollagen C-proteinase enhancer-1 in the remodeling rat heart is stimulated by aldosterone.
Topics: Aldosterone; Animals; Body Weight; Collagen Type I; Glycoproteins; Heart; In Situ Hybridization; Int | 2006 |
Improvement of EDHF by chronic ACE inhibition declines rapidly after withdrawal in rats with myocardial infarction.
Topics: Acetylcholine; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Biological Factors; E | 2005 |
Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Topics: Aldosterone; Animals; Cardiotonic Agents; Drug Interactions; Eplerenone; Heart; Hemodynamics; In Vit | 2006 |
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients.
Topics: Aged; Aldosterone; AMP Deaminase; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Epinephri | 2006 |
High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Electrocardiography; Female; Follow-Up Studies; Humans; | 2006 |
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis; | 2006 |
Aldosterone and cardiovascular disease: smoke and fire.
Topics: Aldosterone; Cardiovascular Diseases; Electrocardiography; Humans; Hyperaldosteronism; Hypertension; | 2006 |
Avoiding vicious circles: mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction.
Topics: Aldosterone; Angiotensin II; Animals; Endothelium, Vascular; Eplerenone; Humans; Mice; Mineralocorti | 2007 |
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Topics: Aldosterone; Animals; Clodronic Acid; Collagen; Cytokines; Eplerenone; Factor XIIIa; Heart Failure; | 2008 |
Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.
Topics: Aged; Aldosterone; Captopril; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Male; Mi | 1983 |
The renin-angiotensin--aldosterone system and the clinical course of acute myocardial infarction.
Topics: Adult; Aged; Aldosterone; Arrhythmias, Cardiac; Epinephrine; Female; Heart Failure; Humans; Male; Mi | 1983 |
Flurbiprofen interaction with single doses of atenolol and propranolol.
Topics: Adult; Aldosterone; Atenolol; Blood Pressure; Body Weight; Female; Flurbiprofen; Heart Rate; Humans; | 1984 |
[Aldosterone, sodium and potassium concentrations in the blood of patients with myocardial infarction after acute hydrocortisone load].
Topics: Adult; Aged; Aldosterone; Female; Humans; Hydrocortisone; Male; Middle Aged; Myocardial Infarction; | 1983 |
Humoral mechanisms of arterial hypertension in patients in the acute phase of myocardial infarction.
Topics: Adult; Aged; Aldosterone; Catecholamines; Female; Hemodynamics; Humans; Hydrocortisone; Hypertension | 1982 |
Effect of enalapril on ventricular remodeling and function during healing after anterior myocardial infarction in the dog.
Topics: Aldosterone; Animals; Collagen; Dogs; Enalapril; Female; Hemodynamics; Male; Myocardial Infarction; | 1995 |
Selective activation of atrial natriuretic peptide in patients with myocardial infarction and mild left ventricular dysfunction.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Female; Humans; Male; Middle Aged; Myocardial I | 1993 |
Atrial natriuretic peptide response is blunted in patients with acute myocardial infarction and mild left ventricular dysfunction.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output, Low; Female; He | 1994 |
Short- and long-term neurohormonal activation following acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Case-Control | 1993 |
Plasma atrial natriuretic factor in uncomplicated acute myocardial infarction.
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Female; Hemodynamics; Humans; Male; Middle Aged | 1993 |
[Effect of cilazapril on exercise tolerance and neurohumoral factors in patients with asymptomatic chronic heart failure after myocardial infarction].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Fact | 1995 |
Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency.
Topics: Adult; Aged; Aldosterone; Cicatrix; Cineangiography; Collagen; Coronary Angiography; Coronary Vessel | 1997 |
Adrenal tumors and pregnancy.
Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Adrenocortical Adenoma; Adult; Aldosterone; Fatal Outc | 1999 |
Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; C | 1999 |
[Role of cardiac aldosterone in post-infarction ventricular remodeling in rats].
Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Myocardial Infarction; Rats; Reverse Transcriptase P | 1999 |
Neurohormones in an ovine model of compensated postinfarction left ventricular dysfunction.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Coronary Vessels; Disease Models, Animal; Endotheli | 2000 |
[Changes in gluco- and mineralocorticoid adrenal functions in rats with inherited arterial hypertension during experimental myocardial infarction].
Topics: Adrenal Glands; Aldosterone; Animals; Corticosterone; Hypertension; Male; Myocardial Infarction; Rat | 2000 |
The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Topics: Aldosterone; Double-Blind Method; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Anta | 2001 |
Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Bronchodilator Agents; Female; Heart F | 2001 |
Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction.
Topics: Acute Disease; Aged; Aldosterone; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhi | 2001 |
Aldosterone and myocardial infarction--are aldosterone antagonists needed to prevent remodelling or does ACE inhibition suffice?
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenoic Acid; Captopril; Cardiomegaly; Huma | 2001 |
Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; | 2002 |
[Disorder of the mineralocorticoid function of the adrenals in the acute period of myocardial infarct and the ways for its correction].
Topics: Acute Disease; Adrenal Gland Diseases; Adult; Aged; Aldosterone; Chronic Disease; Coronary Disease; | 1979 |
[Renin and various factors of its regulation in acute myocardial infarct].
Topics: Acute Disease; Adult; Aged; Aldosterone; Angiotensin II; Homeostasis; Humans; Hypokalemia; Male; Mid | 1978 |
[Activity of adrenal hormones and kallikrein-kinin blood system in acute disorders of the heart rhythm in patients with myocardial infarct].
Topics: 11-Hydroxycorticosteroids; Acute Disease; Adult; Aged; Aldosterone; Arrhythmias, Cardiac; Epinephrin | 1978 |
[Functional morphology of the hypothalamo-hypophyseal neurosecretory system and adrenal cortex in myocardial infarct].
Topics: Adrenal Cortex; Aldosterone; Cell Nucleus; Dihydrolipoamide Dehydrogenase; Glutamate Dehydrogenase; | 1977 |
[Evaluation of the adrenal cortex function in patients with acute myocardial infarct by means of radioisotope micromethods].
Topics: Acute Disease; Adrenal Cortex; Adrenal Glands; Aldosterone; Binding, Competitive; Humans; Hydrocorti | 1976 |
[Certain humoral factors in acute myocardial infarct complicated by cardiogenic shock].
Topics: Adult; Aged; Aldosterone; Catecholamines; Female; Humans; Male; Middle Aged; Myocardial Infarction; | 1975 |
[Changes in the levels of atrial natriuretic factor, aldosterone, cyclic nucleotides and beta 2-microglobulin in patients with myocardial infarction after ultrasonic therapy].
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; beta 2-Microglobulin; Cardiomyopathy, Dilated; Cyclic | 1991 |
[The changes in renin-angiotensin-aldosterone system in acute myocardial infarction and the effects of converting enzyme inhibitor-captopril].
Topics: Adult; Aged; Aldosterone; Angiotensin II; Captopril; Female; Humans; Male; Middle Aged; Myocardial I | 1991 |
Abnormal hormonal and renal responses to saline load in hypertensive patients with parental history of cardiovascular accidents.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Pressure; Cerebrovascular Disorders; Family Hea | 1991 |
Atrial natriuretic peptide in patients with acute myocardial infarction without functional heart failure.
Topics: Aldosterone; Analysis of Variance; Atrial Natriuretic Factor; Catecholamines; Female; Heart Failure; | 1991 |
[Changes in PTCA. A model of ischemia in humans].
Topics: Adenosine Triphosphate; Adult; Aged; Aldosterone; Angina Pectoris; Angioplasty, Balloon, Coronary; A | 1991 |
Transient acute myocardial ischemia increases atrial natriuretic peptide release in men.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Exercise Test; Humans; Male; Middle Aged; Myocardial | 1991 |
Effects of routine heparin therapy on plasma aldosterone concentration.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Embolism; Female; Heparin; Humans; Male; Myocardial | 1991 |
[Renin and aldosterone in the first 24 hours after acute myocardial infarct].
Topics: Aldosterone; Female; Humans; Male; Middle Aged; Myocardial Infarction; Renin; Time Factors | 1991 |
Role of left ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction.
Topics: Aged; Aldosterone; Angiotensin II; Cardiac Catheterization; Diuretics; Female; Hemodynamics; Humans; | 1990 |
Plasma atrial natriuretic factor in low output heart failure syndromes.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Blood Volume; Bradycardia; Cardiac Output, Low; Femal | 1990 |
Plasma atrial natriuretic factor in patients with acute myocardial infarction.
Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Humans; Male; Middle Aged; Myocardial Contraction; My | 1990 |
[Changes in renin activity in patients with acute myocardial infarction].
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Female; Humans; Male; Middle Aged; Myocardial Infarctio | 1990 |
Trace element-hormone-relations in the early course of myocardial infarction.
Topics: Aldosterone; Copper; Humans; Hydrocortisone; Myocardial Infarction; Trace Elements; Triiodothyronine | 1990 |
[Atrial natriuretic factor in cardiogenic shock, in hypovolemic shock and in the bradycardia-hypotension syndrome following acute myocardial infarction].
Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Bradycardia; Cardiac Output, Low; Female; Hemod | 1989 |
[Effect of an early single physical load on hemodynamics and plasma aldosterone level in patients with acute myocardial infarction].
Topics: Adult; Aldosterone; Exercise Therapy; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction | 1989 |
Neurohumoral responses to chronic myocardial infarction in rats.
Topics: Aldosterone; Animals; Arginine Vasopressin; Atrial Natriuretic Factor; Catecholamines; Chronic Disea | 1988 |
Neuroendocrine changes in acute myocardial infarction.
Topics: Aldosterone; Arginine Vasopressin; Captopril; Catecholamines; Humans; Myocardial Infarction; Neurose | 1988 |
[Determination of the cortisol, insulin and aldosterone content of the blood as possible indices of the course and prognosis of myocardial infarct].
Topics: Adult; Aged; Aldosterone; Female; Humans; Hydrocortisone; Insulin; Male; Middle Aged; Myocardial Inf | 1986 |
Hyperkalemic left bundle branch block and hyporeninemic hypoaldosteronism (hyperkalemic left bundle branch block).
Topics: Aged; Aldosterone; Bundle-Branch Block; Diagnosis, Differential; Female; Humans; Hyperkalemia; Kidne | 1986 |
Effect of dilazep on hemoglobin-oxygen affinity in patients with ischemic heart disease.
Topics: 2,3-Diphosphoglycerate; Administration, Oral; Adult; Aged; Aldosterone; Angina Pectoris; Azepines; C | 1985 |
[Neurohumoral aspects of myocardial infarct and its complications].
Topics: 17-Ketosteroids; Adrenal Glands; Adult; Aged; Aldosterone; Epinephrine; Female; Heart Failure; Hemod | 1974 |
Essential hypertension: renin and aldosterone, heart attack and stroke.
Topics: Adult; Aldosterone; Cardiomegaly; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Mid | 1972 |
Role of catecholamines, aldosterone, potassium and lipids in pathophysiology and severity of myocardial infarction-a clinical and experimental study.
Topics: Aldosterone; Animals; Arteriosclerosis; Catecholamines; Coronary Disease; Dogs; Humans; Lipids; Myoc | 1974 |
Pathophysiologic changes in arteriosclerotic and nonarteriosclerotic rats, following isoproterenol-induced myocardial infarction.
Topics: Adrenal Glands; Alanine Transaminase; Aldosterone; Animals; Arteriosclerosis; Aspartate Aminotransfe | 1972 |
[Activity of plasma renin and aldosterone excretion in patients with macrofocal myocardial infarct and its complications].
Topics: Adult; Aged; Aldosterone; Arrhythmias, Cardiac; Female; Humans; Juxtaglomerular Apparatus; Male; Mid | 1973 |
[Biosynthesis of glucocorticoids and mineralocorticoids in dogs' adrenals in experimental myocardial infarct].
Topics: Adrenal Glands; Aldosterone; Animals; Coronary Vessels; Corticosterone; Cortisone; Desoxycorticoster | 1973 |
Isolation and characterization of a sodium retaining substance from pig heart muscle and its role in myocardial infarction.
Topics: Aldosterone; Animals; Diuresis; Myocardial Infarction; Myocardium; Potassium; Sodium; Swine | 1971 |
Metabolic and histopathological consequences of a fatty liver during the acute stages of myocardial infarction in rats.
Topics: Acute Disease; Adrenal Glands; Alanine Transaminase; Aldosterone; Animals; Aspartate Aminotransferas | 1971 |
[Hormonal activity of the adrenals in congestive circulatory insufficiency].
Topics: 17-Hydroxycorticosteroids; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Aldosterone; Cortis | 1971 |
[Some hormonal parameters in the course of myocardial infarct].
Topics: Adrenal Glands; Adrenal Medulla; Adult; Aged; Aldosterone; Catecholamines; Humans; Hydrocortisone; M | 1971 |
Role of aldosterone in myocardial infarction.
Topics: Adult; Aldosterone; Animals; Chromatography; Diet, Sodium-Restricted; Dogs; Humans; Male; Myocardial | 1965 |
[Blood gas and acid-base equilibrium in myocardial infarct].
Topics: Acid-Base Equilibrium; Aldosterone; Alkalosis; Carbon Dioxide; Humans; Myocardial Infarction; Oxygen | 1970 |
[Characteristics of hormonal disorders in myocardial infarct].
Topics: 17-Hydroxycorticosteroids; Aldosterone; Dihydroxyphenylalanine; Dopamine; Epinephrine; Humans; Hydro | 1970 |
Role of sodium-retaining hormones in cardiac control.
Topics: Aldosterone; Animals; Dogs; Myocardial Infarction; Myocardium; Sodium; Stress, Physiological; Swine; | 1970 |
[Changes of aldosteronuria and tetrahydroaldosteronuria in the post-infarct period].
Topics: Adult; Aged; Aldosterone; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis | 1968 |
[The increase of aldosterone in vascular shock].
Topics: Adult; Aged; Aldosterone; Cerebral Hemorrhage; Female; Humans; Intracranial Embolism and Thrombosis; | 1966 |